文献速递免疫规划传染病防控与疫情报告

注射吸毒者中的乙型肝炎病毒疫苗接种——瑞典针具交换项目20年经验

Vaccination against hepatitis B virus among people who inject drugs - A 20year experience from a Swedish needle exchange program.
PubMed 文献 · Vaccine · 2016-11-25

本研究评估了瑞典某针具交换项目1994—2013年纳入的注射吸毒者中乙型肝炎疫苗接种完成率与应答率,并分析对标准方案无应答者追加最多三剂加强针的效果。结果显示,启动接种者1142人,完成标准方案898人(59.2%);基础方案应答率74.8%,追加加强针后升至84.5%。无应答与较高年龄及抗-HCV阳性相关(p<0.001)。

要点

  • 在针具交换项目中提供乙肝疫苗接种具有可行性,多数易感注射吸毒者完成了接种。
  • 注射吸毒者对基础乙肝疫苗方案的应答率相对较低,为74.8%。
  • 对无应答者追加最多三剂加强针后,应答率从74.8%提高至84.5%。

核心结论

  • 在针具交换项目中纳入乙肝疫苗接种具有可行性,多数乙肝易感注射吸毒者完成了接种。
  • 注射吸毒者对乙肝疫苗的应答率相对较低,但追加最多三剂加强针使应答率从74.8%提高至84.5%。

研究设计与样本

  • 对1994—2013年在瑞典某针具交换项目登记、基线无HBV血清学标志(HBsAg/抗-HBc/抗-HBs均阴性)的注射吸毒者,提供三剂标准肌内注射乙型肝炎疫苗(Engerix®-B,葛兰素史克,20μg/mL,计划于第0、1、6个月接种)。
  • 接种应答定义为抗-HBs达到保护水平(⩾10mIU/mL),对无应答者追加最多三剂加强针,每剂后检测抗-HBs。
  • 针具交换项目登记时可获得2352名可识别个体的HBV数据,其中1516人(64.5%)无既往HBV暴露或接种标志。

主要发现

  • 1516名无HBV标志者中,1142人(75.3%)启动接种,898人(59.2%)完成标准接种方案。
  • 800人获得接种后抗-HBs检测结果,其中598人(74.8%)对基础接种方案应答。
  • 追加最多三剂加强针后,共676人(84.5%)达到保护性抗-HBs水平。
  • 对疫苗无应答与较高年龄及抗-HCV阳性相关(p<0.001)。
  • 在疫苗无应答者中观察到18例新发HBV感染,在未完成接种者中观察到30例。

关键数值与推荐

  • 接种应答定义为抗-HBs⩾10mIU/mL。
  • 标准方案为Engerix®-B(葛兰素史克)20μg/mL肌内注射,计划于第0、1、6个月接种。
  • 对无应答者追加最多三剂加强针,每剂后检测抗-HBs。

临床怎么用

  • 作者认为,针具交换项目中纳入乙肝疫苗接种具有可行性,多数乙肝易感注射吸毒者可完成接种。
  • 作者报告,对基础方案无应答者追加最多三剂加强针可提高应答率。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: People who inject drugs (PWID) are at particular risk of hepatitis B virus (HBV) acquisition, but often have poor access or adherence to HBV vaccination. Vaccination against HBV has been offered at a major Swedish needle exchange program (NEP) since 1994. The aim of this study was to evaluate vaccine completion and response rates, and the effect of sequential booster doses to non-responders to the standard vaccination schedule. METHODS: PWID enrolled in the NEP 1994-2013, without serological markers for HBV at baseline (negative for HBsAg/anti-HBc/anti-HBs), were offered a three-dose standard intramuscular vaccination schedule (Engerix®-B, GSK, 20μg/mL, intended to be received at months 0, 1 and 6). Vaccination response was defined as protective levels of anti-HBs (⩾10mIU/mL). Up to three booster doses were then offered for non-responders, each followed by anti-HBs testing. RESULTS: HBV data was available for 2352 identifiable individuals at NEP enrolment, of whom 1516 (64.5%) had no markers for previous HBV exposure or vaccination. Vaccination was initiated for 1142 (75.3%) individuals and 898 (59.2%) completed the standard vaccination schedule. Post-vaccination anti-HBs levels were available from 800 individuals, with 598 (74.8%) responding to the basic vaccination schedule. After up to three booster doses a total of 676 (84.5%) individuals achieved protective anti-HBs levels. Non-response to vaccination was associated with higher age and anti-HCV positivity (p<0.001). Eighteen incident cases of HBV infection were observed among vaccine non-responders, as well as 30 cases among those who had not completed vaccination. CONCLUSION: We demonstrate the feasibility of including HBV vaccination in the services offered by a NEP, with completion of vaccination in a majority of HBV-susceptible PWID. The response to HBV vaccination among PWID was relatively low; however, the addition of up to three booster doses improved the response rate from 74.8 to 84.5%.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Alanko Blomé M, Björkman P, Flamholc L, et al. Vaccination against hepatitis B virus among people who inject drugs - A 20year experience from a Swedish needle exchange program. Vaccine. 2016. PMID: 27894721. doi:10.1016/j.vaccine.2016.11.041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。